TABLE 1

Baseline characteristics of women who returned for at least one follow-up visit after randomization to placebo or troglitazone

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Placebo group | | Troglitazone | | *P* |
| n | 122 | | 114 | |  |
| Clinical characteristics |  |  |  |  |  |
| Age (years) | 34.3 | ±6.5 | 34.9 | ±6.6 | 0.52 |
| BMI (kg/m2) | 30.3 | ±5.3 | 30.6 | ±6.1 | 0.63 |
| Waist-to-hip circumference ratio | 0.86 | ±0.05 | 0.85 | ±0.06 | 0.19 |
| Using hormonal contraceptives\* | 48% | | 43% | | 0.41 |
| OGTT |  |  |  |  |  |
| Fasting glucose (mg/dl) | 98.1 | ±9.1 | 98.7 | ±10.2 | 0.64 |
| 2-h glucose | 154.0 | ±2.0 | 18.9 | ±2.0 | 0.97 |
| Total glucose area (mg/dl X min X 10-3) ‡ | 18.7 | ±9.7 | 16.6 | ±9.5 | 0.25 |
| Impaired glucose tolerance | 72% | | 69% | | 0.66 |
| Fasting insulin (µU/ml X min) ‡ | 16.0 | ±7.5 | 17.0 | ±10.8 | 0.82 |
| Total insulin area (µU/ml X min) | 10,209 | ±5,536 | 9,902 | ±6,543 | 0.55 |